Parkinson's disease pipeline offers potential for breakthrough

Industry analyst GlobalData has outlined what it sees as a significant market opportunity for new entrants targeting Parkinson’s disease (PD).

PD is currently treated with levodopa-based therapies, managing dopamine levels in the brain, an approach which has remained the standard of care for decades.

Long-term options or curative treatments remain elusive, however, as symptoms inevitably return over time.